Methamphetamine-associated Psychosis

Overview

Journal J Neuroimmune Pharmacol

Specialties Allergy & Immunology
Neurology
Pharmacology

Date 2011 Jul 6

PMID 21728034

Citations 84

Authors

Kathleen M Grant

Tricia D LeVan

Sandra M Wells

Ming Li

Scott F Stoltenberg

Howard E Gendelman

Gustavo Carlo

Rick A Bevins

Affiliations

Soon will be listed here.

Abstract

Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.

Citing Articles

Practices and attitudes of adult psychiatrists regarding methamphetamine-associated psychotic disorder: an internet based survey conducted in Turkey.

Orum M, Kapici Y, Sonmez D, Tanrikulu A, Gumusay M, Kochan O BMC Health Serv Res. 2025; 25(1):20.

PMID: 39754117 PMC: 11699667. DOI: 10.1186/s12913-024-12134-1.

Urinary Retention Following Methamphetamine and Cannabis Abuse in a 33-Year-Old Male.

Kaur N, Haleem M, Espiridion E Cureus. 2024; 16(3):e57033.

PMID: 38681277 PMC: 11047220. DOI: 10.7759/cureus.57033.

Factors Associated with Psychotic and Depressive Symptoms in Methamphetamine Users.

Karabulut S Iran J Psychiatry. 2024; 19(1):1-10.

PMID: 38420276 PMC: 10896751. DOI: 10.18502/ijps.v19i1.14334.

Hyperconnectivity of the lateral amygdala in long-term methamphetamine abstainers negatively correlated with withdrawal duration.

Li Y, Wang X, Huang S, Huang Q, Yang R, Liao Z Front Pharmacol. 2023; 14:1138704.

PMID: 38026924 PMC: 10668120. DOI: 10.3389/fphar.2023.1138704.

A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine.

Moran R, Hastings C, Della-Pietra U, Singh C, Jacome M Cureus. 2023; 15(10):e47135.

PMID: 38021522 PMC: 10650934. DOI: 10.7759/cureus.47135.

References

Zweben J, Cohen J, Christian D, Galloway G, Salinardi M, Parent D . Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2):181-90. DOI: 10.1080/10550490490436055. View

Kobayashi H, Ide S, Hasegawa J, Ujike H, Sekine Y, Ozaki N . Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann N Y Acad Sci. 2004; 1025:325-34. DOI: 10.1196/annals.1316.040. View

Lemonde S, Turecki G, Bakish D, Du L, Hrdina P, Bown C . Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003; 23(25):8788-99. PMC: 6740417. View

Glasner-Edwards S, Mooney L, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R . Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008; 35(4):445-50. DOI: 10.1016/j.jsat.2007.12.004. View

Chang L, Alicata D, Ernst T, Volkow N . Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007; 102 Suppl 1:16-32. DOI: 10.1111/j.1360-0443.2006.01782.x. View

Ikeda M, Ozaki N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y . Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav. 2007; 6(1):107-12. DOI: 10.1111/j.1601-183X.2006.00237.x. View

Badner J, Gershon E . Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002; 7(4):405-11. DOI: 10.1038/sj.mp.4001012. View

Thomas D, Walker P, Benjamins J, Geddes T, Kuhn D . Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004; 311(1):1-7. DOI: 10.1124/jpet.104.070961. View

Segal D, Kuczenski R . Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp Ther. 1999; 291(1):19-30. View

10.

Chen C, Lin S, Sham P, Ball D, Loh E, Hsiao C . Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003; 33(8):1407-14. DOI: 10.1017/s0033291703008353. View

11.

van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H . Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002; 156(4):319-27. DOI: 10.1093/aje/kwf043. View

12.

Braff D, Geyer M, Light G, Sprock J, Perry W, Cadenhead K . Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001; 49(1-2):171-8. DOI: 10.1016/s0920-9964(00)00139-0. View

13.

Tsunoka T, Kishi T, Kitajima T, Okochi T, Okumura T, Yamanouchi Y . Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(4):639-44. DOI: 10.1016/j.pnpbp.2010.03.002. View

14.

Mizoguchi H, Arai S, Koike H, Ibi D, Kamei H, Nabeshima T . Therapeutic potential of nicotine for methamphetamine-induced impairment of sensorimotor gating: involvement of pallidotegmental neurons. Psychopharmacology (Berl). 2009; 207(2):235-43. DOI: 10.1007/s00213-009-1651-z. View

15.

Kosloski L, Ha D, Hutter J, Stone D, Pichler M, Reynolds A . Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem. 2010; 114(5):1261-76. PMC: 2923270. DOI: 10.1111/j.1471-4159.2010.06834.x. View

16.

Volkow N, Chang L, Wang G, Fowler J, Franceschi D, Sedler M . Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001; 21(23):9414-8. PMC: 6763886. View

17.

Kew J, Pflimlin M, Kemp J, Mutel V . Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice. Neuropharmacology. 2002; 43(2):215-21. DOI: 10.1016/s0028-3908(02)00084-9. View

18.

Kishi T, Tsunoka T, Ikeda M, Kawashima K, Okochi T, Kitajima T . Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. J Hum Genet. 2009; 54(11):629-33. DOI: 10.1038/jhg.2009.84. View

19.

Bevins R, Peterson J . Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol Biochem Behav. 2004; 79(1):65-74. DOI: 10.1016/j.pbb.2004.06.002. View

20.

Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N . Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci. 2004; 1025:316-24. DOI: 10.1196/annals.1316.039. View